Vertebroplasty data hint atnegative effect on survival
Researchers were stunned when preliminary results of an ongoing study showed that patients who undergo vertebroplasty may die sooner than patients with vertebral fractures who do not undergo the procedure.
Researchers were stunned when preliminary results of an ongoing study showed that patients who undergo vertebroplasty may die sooner than patients with vertebral fractures who do not undergo the procedure.
“It doesn’t make any sense to us,” said coauthor Dr. Robert J. McDonald from Mayo Clinic’s Medical Scientist Training Program.
McDonald and colleagues in Rochester, MN, compared survival rates of patients treated with vertebroplasty for vertebral fractures with those treated conservatively. A preliminary data analysis suggested the former had a significantly reduced life expectancy when compared with the latter.
The study remains a work-in-progress, however, and McDonald advised against jumping to conclusions before final results are in. He released the preliminary findings at the 2008 RSNA meeting.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
